Análisis Argos
TECH
TECHCara
Bio-Techne Corporation · Healthcare
US$ 70.83
precio al 2026-07-04
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
45/100
LA RESPUESTA
El mercado le pide crezca 44.5% al año — más de lo que ha demostrado (2.8%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
Sin recompensas destacadas.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
VALOR1/6FUTURO3/6PASADO2/6SALUD4/6DIVIDENDO3/6
El Iris de calidad
VALOR1/6FUTURO3/6PASADO2/6SALUD4/6DIVIDENDO3/6
ValorCotiza por encima de su valor justo
FuturoCrecimiento moderado
PasadoHistorial aceptable
SaludBalance fuerte, deuda controlada
DividendoRetorno al accionista moderado
Score Argos45de 100Cara
Ingresos5%
US$ 1.2 B
Margen operativo53%
8.4%
Flujo de caja libre8%
US$ 0.3 B
Deuda neta
US$ 0.3 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 11.1B
P/E151.1x
EV/EBITDA53.6x
FCF yield2.3%
ROIC3.5%
Margen operativo8.4%
Crecim. ingresos+5.2%/año
Piotroski F5/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

globenewswire.com · 2 jul
Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.
globenewswire.com · 2 jul
Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.
globenewswire.com · 30 jun
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)
BALA CYNWYD, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
businesswire.com · 29 jun
Bio-Techne Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Bio-Techne Corporation - TECH
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Bio-Techne Corporation (NasdaqGS: TECH) to Merck KGaA. Under the terms of the proposed transaction, shareholders of Bio-Techne will receive $73.00 in cash for each share of Bio-Techne that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.
gurufocus.com · 29 jun
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 29, 2026
prnewswire.com · 29 jun
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
globenewswire.com · 29 jun
CMB.TECH fleet update
ANTWERP, Belgium, 29 June 2026, 08:00 CET – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) has sold two Suezmaxes, generating a capital gain of approximately 100.5 million USD.
prnewswire.com · 26 jun
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bio-Techne Corporation (NASDAQ: TECH)
NEW YORK, June 26, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Bio-Techne Corporation (NASDAQ: TECH ) related to its sale to Merck KGaA.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.